CLDX
Celldex Therapeutics, Inc.
$29.36
-0.81%
$2.3B
No data for this timeframe.
Vol
Market Cap$2.3B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders8 funds
Inst. Value$286.0M
Inst. Activity2 buys / 1 sells
Reddit Sentiment60° Warm
SEC Reports4
Press Releases5
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. DE·CIK 0000744218·Prev Close $29.60
Recent Activity
May 7, 2026
SEC
Celldex reported Q1 2026 results with a net loss of $78.7M (-$1.18/share), wider than the $53.8M loss (-$0.81/share) in
8-K — Impact 6/10
May 7, 2026
SEC
Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K), reflecting wideni
PRESS-RELEASE — Impact 6/10
Apr 1, 2026
SEC
Celldex Therapeutics is conducting a follow-on public offering of common stock to raise capital. The proceeds will fund
424B5 — Impact 5/10
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
132,533 shares ($3.6M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
118,488 shares ($3.2M)
May 7, 2026
earnings
Celldex Reports First Quarter Financial Results and Provides Corporate Update
<p>HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial
Apr 6, 2026
Press
Celldex Therapeutics closed an underwritten public offering of 11.9 million shares at $29.00 per share, raising approxim
Impact 5/10
Apr 2, 2026
Press
Celldex Therapeutics priced a public offering of 10,345,000 shares at $29.00 per share, raising approximately $300 milli
Impact 5/10
Price Targets
$58.43
+99.0% upside
Strong Buy
Current $29.36
Low $38.00
Median $58.00
High $90.00
14 analysts
$38.00
$90.00
Analyst Ratings
7Strong Buy
13Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 10, 2026 | UBS | MAINTAIN | Buy → Buy |
| May 13, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 8, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 20, 2026 | Barclays | UPGRADE | Underweight → Overweight |
| Mar 2, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.06 ▲ +11.4% | $-1.16 — $-0.92 | -25% YoY | 9 |
| Next Q | $-1.08 ▲ +12.3% | $-1.20 — $-0.94 | -7% YoY | 9 |
| Current FY | $-4.39 ▲ +7.1% | $-4.57 — $-4.03 | -13% YoY | 9 |
| Next FY | $-4.55 ▲ +4.5% | $-5.46 — $-3.78 | -4% YoY | 9 |
Latest Reports
MIXED
8-K
6/10
Celldex reported Q1 2026 results with a net loss of $78.7M (-$1.18/share), wider than the $53.8M loss (-$0.81/share) in
May 7, 2026
MIXED
PRESS-RELEASE
6/10
Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K), reflecting wideni
May 7, 2026
NEUTRAL
Press
5/10
Celldex Therapeutics closed an underwritten public offering of 11.9 million shares at $29.00 per share, raising approxim
Apr 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $133.3M | — |
| VANGUARD GROUP INC | $109.4M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $15.0M | NEW |
| BANK OF AMERICA CORP | $11.3M | — |
| MORGAN STANLEY | $7.8M | TRIM |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $286.0M total value (10,528,648 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, CHARLES. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 4,907,469 | $133.3M | 46.6% | — |
| 2 | VANGUARD GROUP INC | 4,027,407 | $109.4M | 38.3% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 550,729 | $15.0M | 5.2% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 414,888 | $11.3M | 3.9% | — |
| 5 | MORGAN STANLEY | 285,535 | $7.8M | 2.7% | TRIM -52.8% |
| 6 | TWO SIGMA INVESTMENTS, LP | 132,533 | $3.6M | 1.3% | ADD +80.6% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 118,488 | $3.2M | 1.1% | TRIM -39.1% |
| 8 | WELLS FARGO & COMPANY/MN | 91,599 | $2.5M | 0.9% | ADD +35.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 73,401 | 132,533 | +80.6% | $3.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 194,588 | 118,488 | -39.1% | $3.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 67,756 | 91,599 | +35.2% | $2.5M | 2025-Q4 |
| UBS Group AG | TRIM | 841,246 | 416,447 | -50.5% | $10.8M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 661,518 | 311,919 | -52.8% | $8.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 43,276 | 67,756 | +56.6% | $1.8M | 2025-Q3 |
| UBS Group AG | TRIM | 1,468,240 | 841,246 | -42.7% | $17.1M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 902,882 | 661,518 | -26.7% | $13.5M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 28,656 | 80,733 | +181.7% | $1.6M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 33,378 | 43,276 | +29.7% | $880.7K | 2025-Q2 |
| UBS Group AG | DOUBLED | 389,797 | 1,468,240 | +276.7% | $26.6M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,344,099 | 902,882 | -32.8% | $16.4M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 101,398 | 33,378 | -67.1% | $605.8K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 435,818 | 1,344,099 | +208.4% | $34.0M | 2024-Q4 |
| UBS Group AG | DOUBLED | 166,597 | 389,797 | +134.0% | $9.9M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 136,588 | — | $3.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 22,411 | 101,398 | +352.4% | $2.6M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 538,856 | — | $18.3M | 2024-Q3 |
| MORGAN STANLEY | DOUBLED | 163,992 | 435,818 | +165.8% | $14.8M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 2 mixed, 1 neutral. Avg impact: 6.0/10.
MIXED
8-K
6/10
Celldex reported Q1 2026 results with a net loss of $78.7M (-$1.18/share), wider than the $53.8M los
May 7, 2026
MIXED
PRESS-RELEASE
6/10
Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K
May 7, 2026
NEUTRAL
424B5
5/10
Celldex Therapeutics is conducting a follow-on public offering of common stock to raise capital. The
Apr 1, 2026
BULLISH
INST-CLUSTER
7/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
NEUTRAL
5/10
Celldex Therapeutics closed an underwritten public offering of 11.9 million shares at $29.00 per sha
Apr 6, 2026
NEUTRAL
5/10
Celldex Therapeutics priced a public offering of 10,345,000 shares at $29.00 per share, raising appr
Apr 2, 2026
NEUTRAL
4/10
Celldex Therapeutics announced a public offering of its common stock, with underwriters granted a 30
Apr 1, 2026
BULLISH
8/10
Celldex Therapeutics presented positive Phase 2 data for barzolvolimab in chronic spontaneous urtica
Mar 27, 2026
BULLISH
8/10
Celldex Therapeutics presented positive Phase 2 open-label extension data for barzolvolimab in ColdU
Mar 1, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 22 analysts: 7 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$58.43 mean target
+99.0% upside
Strong Buy (3.00)
$38.00 Low
$90.00 High
| Metric | Value |
|---|---|
| Current Price | $29.36 |
| Target Low | $38.00 |
| Target Mean | $58.43 |
| Target Median | $58.00 |
| Target High | $90.00 |
| # Analysts | 14 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.06 | $-1.16 | $-0.92 | -24.9% | +11.4% | 4↑ 0↓ | $0.0B | 17.7% | 9 |
| Next Q 2026-09-30 |
$-1.08 | $-1.20 | $-0.94 | -6.9% | +12.3% | 4↑ 1↓ | $0.0B | 0.0% | 9 |
| Current FY 2026-12-31 |
$-4.39 | $-4.57 | $-4.03 | -12.6% | +7.1% | 6↑ 0↓ | $0.0B | 70.5% | 9 |
| Next FY 2027-12-31 |
$-4.55 | $-5.46 | $-3.78 | -3.6% | +4.5% | 6↑ 1↓ | $0.0B | 241.9% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.061 | |
| 7d ago | $-1.182 | +0.120 |
| 30d ago | $-1.198 | +0.137 |
| 60d ago | $-1.215 | +0.154 |
| 90d ago | $-1.088 | +0.027 |
5 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 10, 2026 | UBS | MAINTAIN | Buy | Buy |
| May 13, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 8, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 20, 2026 | Barclays | UPGRADE | Underweight | Overweight |
| Mar 2, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Feb 26, 2026 | Stifel | REITERATE | Buy | Buy |
| Dec 17, 2025 | Barclays | MAINTAIN | Underweight | Underweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Apr 1, 2026 | 7 | 12 | 2 | 1 | 0 | 86% | |
| Mar 1, 2026 | 6 | 12 | 3 | 1 | 0 | 82% | |
| Feb 1, 2026 | 6 | 12 | 3 | 1 | 0 | 82% | |
| Jan 1, 2026 | 6 | 12 | 3 | 1 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 1, 2026
Clinical Trial
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
Phase Phase 2 — COMPLETED
May 7, 2026
earnings
Celldex Reports First Quarter Financial Results and Provides Corporate Update
<p>HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026
Apr 30, 2026
earnings_calendar
CLDX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 29, 2026
Clinical Trial
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Phase Phase 2 — COMPLETED
Apr 13, 2026
other
Celldex to Present at Upcoming Investor Conference
<p align="justify">HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fir
Apr 6, 2026
activist
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p>HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the clos
Apr 2, 2026
offering
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
<p align="justify">HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today an
Apr 2, 2026
Clinical Trial
A Study of Barzolvolimab in Patients With Prurigo Nodularis
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 2, 2026
clinical_trial_readout
T-60d Trial Readout: barzolvolimab (Phase 2)
Trial: A Study of Barzolvolimab in Patients With Prurigo Nodularis
Sponsor: Celldex Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Condit
Apr 1, 2026
offering
Celldex Announces Proposed Public Offering of Common Stock
<p align="justify">HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today an
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: barzolvolimab (Phase 2)
Trial: A Study of Barzolvolimab in Patients With Prurigo Nodularis
Sponsor: Celldex Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Condit
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: barzolvolimab (Phase 2)
Trial: A Study of Barzolvolimab in Patients With Prurigo Nodularis
Sponsor: Celldex Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Condit
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: barzolvolimab (Phase 2)
Trial: A Study of Barzolvolimab in Patients With Prurigo Nodularis
Sponsor: Celldex Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Condit
Mar 27, 2026
fda
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
<p><em>- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -</em><br><em>- Data further d</em><em>e
Mar 23, 2026
short_volume
Short Volume: CLDX — 57.3% short (0.4M / 0.7M)
Short: 406,075 | Exempt: 0 | TRF Vol: 708,936 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Mar 2, 2026
earnings_calendar
CLDX Q4 2025 Earnings After Market Close — 2026-03-02
Mar 1, 2026
fda
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
<p><em>- Late breaking Poster Presentation at AAAAI -</em><br><em>- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU
Feb 12, 2026
short_interest
FTD: CLDX — 43,753 shares ($1.1M) failed to deliver
Settlement: 20260212, Price: $24.60, FTD Value: $1,076,323.8, CELLDEX THERAPEUTICS INC NEW C